Impulse Biomedical, a Cape Town-based healthcare company focused on advancing asthma and allergy care through developing more accessible and patient-focused products, is excited to announce its acceptance into the Maryland Global Gateway Soft Landing Program, which marks a major milestone in its global expansion plans. The company, focused on developing and commercializing its patented ZiBiPen^® reloadable autoinjector and patented Easy Squeezy^® asthma assist device, addresses key global health-related challenges that significantly impact communities.

The Maryland Department of Commerce officially welcomed Impulse into the Global Gateway Program on May 5th, with an announcement on their website. The program provides international companies with the support and resources to establish a US presence, including access to facilities, capital, and partner advisors who have appropriate industry knowledge to support the growth of the companies.

“We are truly honoured to be part of the program as establishing our US presence through the Maryland Global Gateway program is a pivotal milestone for Impulse Biomedical,” said Giancarlo Beukes, Co-Founder. “The strategic support from the Maryland Department of Commerce and the specialised expertise at The LaunchPort will be key in smoothing our transition into the US market, ensuring we are well positioned for long-term success and impact.”

This sentiment was echoed by fellow Co-Founder Gokul Nair. “We believe that Maryland is the ideal launchpad for the ZiBiPen® in particular. The ecosystem offers a direct line to regulatory expertise, manufacturing infrastructure, and commercial partners essential for market disruption and of course, impact.”

As part of Impulse’s global expansion strategy, the company officially took up residence at The LaunchPort, a Medtech manufacturing accelerator in Baltimore, MD, earlier this year. The move was facilitated by ANZA Capital, one of Impulse’s lead investors, aiming to unlock new strategic pathways to support the company’s growth: “ANZA is proud to back bold African Founders like Giancarlo and Gokul. Through our Board Director, Robert E. Williams, we are pleased to facilitate this bridge to the U.S. for our portfolio companies, with Impulse leading the way,” said Audrey Verhaeghe, CEO, ANZA Capital.

During the company’s residency at The Launchport, Impulse will focus on establishing local operations, engaging with regulators to guide a US approval processes, and will explore a manufacturing and sterilization partnership with The Launchport.

About

Impulse Biomedical is a healthcare company focused on disrupting the allergy and immunology markets, leveraging patient-centric design to ensure life-saving treatments are accessible and user-friendly. Our flagship product, the ZiBiPen®, is a world-first reloadable epinephrine auto-injector, utilizing a globally patented technology that replaces only the medication cartridge upon expiry, to reduce costs and medical waste. Complementing this is the Easy Squeezy®, a patented ergonomic inhaler sleeve that reduces activation force by 4X, clinically proven to improve lung function and asthma control. With over 22,000 units sold in South Africa, we are proud to announce that Easy Squeezy® is now available in the UK as well.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260511915309/en/